Sponsors (4)
The bill expedites VA research and access to novel psychedelic and related therapies for veterans—potentially improving care for hard-to-treat conditions—but raises substantial safety, evidence, funding, and implementation risks that could divert resources or lead to premature, widespread use.
Veterans with PTSD, depression, chronic pain, or substance use disorders could gain faster access to clinical trials and expanded use of psychedelic- and entactogenic-assisted therapies.
A VA research focus and VA-run trials could generate preliminary evidence on the safety and effectiveness of novel therapies, informing future evidence-based care for veterans.
Centralizing research and care within VA clinics can improve care coordination and access for enrolled veterans by providing services inside existing VA health systems.
Veterans could be exposed to investigational psychedelic or entactogenic treatments that have incomplete safety and long-term efficacy evidence, including risks of serious adverse effects.
The program may shift existing VA funds toward research and experimental therapies, potentially reducing funding for other proven VA services unless Congress provides new appropriations or offsets.
Preliminary or early positive outcomes reported within a short timeframe could increase patient demand and political pressure for wider use before robust evidence is available, risking premature adoption.
Based on analysis of 3 sections of legislative text.
Requires the Department of Veterans Affairs to set up an investigational research program to evaluate and, where appropriate, provide veteran access to specified innovative treatments and emerging therapies (including several psychedelic and entactogenic substances, ketamine, investigational devices, and other therapies the Secretary may designate) for conditions such as chronic pain, PTSD, depression, anxiety, substance use disorders, and traumatic brain injury. The VA must create the program quickly (lead administrator within 60 days; program developed within 90 days), may run clinical trials and compassionate/extended access protocols, use VA-authorized funds already available, report findings and clinic locations to congressional veterans committees within one year, and review the program within two years for extension or termination, while implementing the program consistent with applicable federal law including investigational product and controlled-substance requirements.
Introduced January 15, 2026 by John Bergman · Last progress January 15, 2026